Unknown

Dataset Information

0

Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments.


ABSTRACT: Radionuclide therapies are an important tool for the management of patients with neuroendocrine neoplasms (NENs). Especially [131I]MIBG and [177Lu]Lu-DOTA-TATE are routinely used for the treatment of a subset of NENs, including pheochromocytomas, paragangliomas and gastroenteropancreatic tumors. Some patients suffering from other forms of NENs, such as medullary thyroid carcinoma or neuroblastoma, were shown to respond to radionuclide therapy; however, no general recommendations exist. Although [131I]MIBG and [177Lu]Lu-DOTA-TATE can delay disease progression and improve quality of life, complete remissions are achieved rarely. Hence, better individually tailored combination regimes are required. This review summarizes currently applied radionuclide therapies in the context of NENs and informs about recent advances in the development of theranostic agents that might enable targeting subgroups of NENs that previously did not respond to [131I]MIBG or [177Lu]Lu-DOTA-TATE. Moreover, molecular pathways involved in NEN tumorigenesis and progression that mediate features of radioresistance and are particularly related to the stemness of cancer cells are discussed. Pharmacological inhibition of such pathways might result in radiosensitization or general complementary antitumor effects in patients with certain genetic, transcriptomic, or metabolic characteristics. Finally, we provide an overview of approved targeted agents that might be beneficial in combination with radionuclide therapies in the context of a personalized molecular profiling approach.

SUBMITTER: Richter S 

PROVIDER: S-EPMC10750207 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature

altmetric image

Publications

Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments.

Richter Susan S   Steenblock Charlotte C   Fischer Alessa A   Lemm Sandy S   Ziegler Christian G CG   Bechmann Nicole N   Nölting Svenja S   Pietzsch Jens J   Ullrich Martin M  

Theranostics 20240101 1


Radionuclide therapies are an important tool for the management of patients with neuroendocrine neoplasms (NENs). Especially [<sup>131</sup>I]MIBG and [<sup>177</sup>Lu]Lu-DOTA-TATE are routinely used for the treatment of a subset of NENs, including pheochromocytomas, paragangliomas and gastroenteropancreatic tumors. Some patients suffering from other forms of NENs, such as medullary thyroid carcinoma or neuroblastoma, were shown to respond to radionuclide therapy; however, no general recommenda  ...[more]

Similar Datasets

| S-EPMC8118168 | biostudies-literature
| S-EPMC7697910 | biostudies-literature
| S-EPMC7960621 | biostudies-literature
| S-EPMC9390818 | biostudies-literature
| S-EPMC7205451 | biostudies-literature
| S-EPMC9496842 | biostudies-literature
2024-03-01 | GSE213504 | GEO
| S-EPMC9292713 | biostudies-literature
| S-EPMC10750196 | biostudies-literature
| S-EPMC8772950 | biostudies-literature